Physician profile
Lisa Buschmann
NPI 1396180881
$1,768.34
in general payments reported to CMS, 2019-2025
23 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2021: $258 · 2022: $175 · 2023: $348 · 2024: $174 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.51 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Intuitive Surgical, INC. | $290.98 | 2019 | |
| Coopersurgical, INC. | $161.94 | 2019-2024 | Paragard T 380a, Summit Doppler, Paragard T 380a |
| Organon LLC | $155.02 | 2021-2024 | Nexplanon |
| Astellas Pharma US INC | $109.62 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $84.32 | 2023-2025 | Aptima, Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $67.28 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $57.56 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $49.81 | 2019 | |
| Amag Pharmaceuticals, INC. | $43.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.38 | 2019-2022 | |
| Millicent US INC | $35.55 | 2019-2023 | Femring, Intrarosa |
| Boston Scientific Corporation | $35.50 | 2019-2022 | |
| Pfizer INC. | $32.72 | 2019-2021 | |
| Exeltis, USA INC. | $28.97 | 2023-2025 | Slynd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.94 | 2023 | Myfembree |
| Mylan Pharmaceuticals INC. | $19.14 | 2022 | |
| Amgen INC. | $16.34 | 2019 | |
| Minerva Surgical, INC | $15.19 | 2023 | |
| Avion Pharmaceuticals | $14.73 | 2023 | Balcoltra |
| Myriad Women'S Health, INC. | $14.32 | 2023 | Myrisk |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.65 | 2021 | |
| Daiichi Sankyo INC. | $10.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Buschmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.